Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02630836

Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture

A Pilot Clinical Trial of ex Vivo Expanded Allogenic Adult Stem Cells Combined With Allogenic Human Bone Tissue (XCEL-MT-OSTEO-BETA) in Proximal Femur Fractures in Elderly Patients

Status
Withdrawn
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Banc de Sang i Teixits · Academic / Other
Sex
All
Age
70 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Prospective, unicenter, randomized, open-label, single-dose, two-arms blinded assessor pilot study. Thirty-two (32) elderly patients with hip fracture will be randomized to one of the two treatment-arms (Xcel-MT-osteo-beta or Standard treatment) and be followed for 12 month with the primary objective of safety. Secondary objectives are efficacy through axial tomography and xRay, clinical efficacy and quality of life questionnaire.

Detailed description

Prospective, unicenter, randomized, open-label, single-dose, two-arms blinded assessor phase I-II pilot study. Thirty-two (32) elderly patients (70-85 years of age) with type 31A2 y 31A3 fracture of the femur (AO/ASIF (Association for the Study of Internal Fixation) classification) admitted at the emergency room of the Hospital Clinic of Barcelona will be randomized 1:1 to one of the two treatment-arms (endomedullary nailing + XCEL-MT-OSTEO-BETA or isolated endomedullary nailing as the standard treatment). Once surgically treated, patients will be followed for 12 month with the primary objective of safety. Secondary objectives are efficacy through axial tomography and xRay, clinical efficacy and quality of life questionnaire (EUROQOL-5D).

Conditions

Interventions

TypeNameDescription
DRUGXCEL-MT-OSTEO-BETAXCEL-MT-OSTEO-BETA followed by endomedullary nailing
PROCEDURESurgical treatmentIsolated endomedullary nailing

Timeline

Start date
2015-12-01
Primary completion
2017-12-01
Completion
2018-12-01
First posted
2015-12-15
Last updated
2017-03-17

Source: ClinicalTrials.gov record NCT02630836. Inclusion in this directory is not an endorsement.